CY1119192T1 - Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα - Google Patents

Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα

Info

Publication number
CY1119192T1
CY1119192T1 CY20171100845T CY171100845T CY1119192T1 CY 1119192 T1 CY1119192 T1 CY 1119192T1 CY 20171100845 T CY20171100845 T CY 20171100845T CY 171100845 T CY171100845 T CY 171100845T CY 1119192 T1 CY1119192 T1 CY 1119192T1
Authority
CY
Cyprus
Prior art keywords
crystal method
bio availability
bio
availability
vitro
Prior art date
Application number
CY20171100845T
Other languages
English (en)
Inventor
Mazen Hanna
Ning Shan
Miranda L Cheney
David R Weyna
Raymond Houck
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/847,568 external-priority patent/US8399023B2/en
Priority claimed from PCT/US2010/043916 external-priority patent/WO2011014781A1/en
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1119192T1 publication Critical patent/CY1119192T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Παρασκευή και in vitro και in vivo χαρακτηρισμός νέων μορφών δραστικών φαρμακευτικών συστατικών, κατάλληλων για φαρμακευτικές συνθέσεις σε συστήματα απελευθέρωσης φαρμάκου για ανθρώπους.
CY20171100845T 2010-02-06 2017-08-07 Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα CY1119192T1 (el)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US30211010P 2010-02-06 2010-02-06
US31287910P 2010-03-11 2010-03-11
US31850310P 2010-03-29 2010-03-29
US33302810P 2010-05-10 2010-05-10
US33304110P 2010-05-10 2010-05-10
US35954410P 2010-06-29 2010-06-29
US12/847,568 US8399023B2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
PCT/US2010/043892 WO2011014766A2 (en) 2009-07-31 2010-07-30 Crystallization method and bioavailability
PCT/US2010/043916 WO2011014781A1 (en) 2009-07-31 2010-07-30 Novel oral forms of a phosphonic acid derivative
US37981410P 2010-09-03 2010-09-03
US45577810P 2010-10-26 2010-10-26
PCT/US2011/023427 WO2011097269A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Publications (1)

Publication Number Publication Date
CY1119192T1 true CY1119192T1 (el) 2018-02-14

Family

ID=44355747

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100845T CY1119192T1 (el) 2010-02-06 2017-08-07 Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα

Country Status (15)

Country Link
EP (1) EP2531200B1 (el)
JP (2) JP5792748B2 (el)
AU (2) AU2012216632B2 (el)
CA (1) CA2826548A1 (el)
CY (1) CY1119192T1 (el)
DK (1) DK2531200T3 (el)
ES (1) ES2638072T3 (el)
HR (1) HRP20171201T1 (el)
HU (1) HUE035744T2 (el)
IL (1) IL221306A0 (el)
LT (1) LT2531200T (el)
PL (1) PL2531200T3 (el)
PT (1) PT2531200T (el)
SI (1) SI2531200T1 (el)
WO (1) WO2011097269A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014781A1 (en) 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
LT2531200T (lt) * 2010-02-06 2017-09-25 Grünenthal GmbH Kristalizacijos būdas ir bioprieinamumas
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102268023B (zh) * 2011-08-15 2013-04-17 南京丰融化学技术有限公司 头孢类衍生物cxd的晶型
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
CA2873742C (en) * 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
ES2884123T3 (es) * 2013-03-15 2021-12-10 Xortx Therapeutics Inc Formulaciones de inhibidores de xantina oxidasa
CN105960240B (zh) * 2013-10-25 2018-04-20 安泰赛普生物风投二代有限责任公司 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物
WO2017049294A1 (en) * 2015-09-18 2017-03-23 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180069277A (ko) * 2016-12-15 2018-06-25 제이투에이치바이오텍 (주) 3성분 코크리스탈
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
EP1612212A1 (en) * 2003-07-03 2006-01-04 Teva Pharmaceutical Industries Ltd Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
US20060068010A1 (en) 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PT2459176T (pt) * 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
LT2531200T (lt) * 2010-02-06 2017-09-25 Grünenthal GmbH Kristalizacijos būdas ir bioprieinamumas
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102070668B (zh) * 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法

Also Published As

Publication number Publication date
JP6190429B2 (ja) 2017-08-30
HUE035744T2 (en) 2018-05-28
AU2016219653A1 (en) 2016-09-15
JP2016006096A (ja) 2016-01-14
WO2011097269A1 (en) 2011-08-11
WO2011097269A9 (en) 2012-12-27
CA2826548A1 (en) 2011-08-11
IL221306A0 (en) 2012-10-31
PT2531200T (pt) 2017-08-24
JP2013519632A (ja) 2013-05-30
AU2016219653B2 (en) 2018-05-31
EP2531200A4 (en) 2014-01-08
DK2531200T3 (en) 2017-09-11
EP2531200B1 (en) 2017-07-12
PL2531200T3 (pl) 2017-10-31
AU2012216632B2 (en) 2016-05-26
ES2638072T3 (es) 2017-10-18
EP2531200A1 (en) 2012-12-12
HRP20171201T1 (hr) 2017-10-06
JP5792748B2 (ja) 2015-10-14
SI2531200T1 (sl) 2017-12-29
LT2531200T (lt) 2017-09-25

Similar Documents

Publication Publication Date Title
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CY1121952T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
CY1121472T1 (el) Συστημα οφθαλμικης αποδεσμευσης φαρμακου που περιεχει φωσφολιπιδιο και χοληστερολη
CO2018003558A2 (es) Método de cristalización y biodisponibilidad
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
PH12014502778B1 (en) Antibody formulation
TW201129382A (en) Antibody formulation and therapeutic regimens
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
EP2600834A4 (en) COLLAGEN IMPLANTS FOR THE SUSTAINABLE DELIVERY OF MEDICAMENTS
MX2012010114A (es) Formulaciones concentradas de proteina y usos de las mismas.
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
EE05760B1 (et) Ravimkoostis
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
BR112013030644A2 (pt) fosfolipídios contendo ácido(s) nitrocarboxílico(s) da estrutura geral (i), e uso dos mesmos, dispositivo médico e composições biopassivadoras
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
PH12015502556A1 (en) Modified release formulation
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
MX2013005820A (es) Peptido derivado de lactoferrina humana para usarse como agente de enmascaramiento de antigenos.
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
EA201400444A1 (ru) Производные 2-оксопиперидинила
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"